TSE:7779

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

CYBERDYNE Inc. manufactures and sells medical devices in Japan.


Snowflake Analysis

High growth potential with excellent balance sheet.


Similar Companies

Share Price & News

How has CYBERDYNE's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 7779's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.6%

7779

0.5%

JP Medical Equipment

2.8%

JP Market


1 Year Return

-7.4%

7779

27.7%

JP Medical Equipment

5.4%

JP Market

Return vs Industry: 7779 underperformed the JP Medical Equipment industry which returned 27.7% over the past year.

Return vs Market: 7779 underperformed the JP Market which returned 5.4% over the past year.


Shareholder returns

7779IndustryMarket
7 Day-1.6%0.5%2.8%
30 Day18.7%13.2%12.4%
90 Day5.9%10.3%9.3%
1 Year-7.4%-7.4%28.8%27.7%8.2%5.4%
3 Year-66.2%-66.2%71.2%66.3%9.9%2.4%
5 Year-67.0%-67.0%92.6%83.0%14.2%1.7%

Price Volatility Vs. Market

How volatile is CYBERDYNE's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is CYBERDYNE undervalued compared to its fair value and its price relative to the market?

2.44x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 7779's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 7779's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 7779 is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: 7779 is unprofitable, so we can't compare its PE Ratio to the JP market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 7779's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 7779 is overvalued based on its PB Ratio (2.4x) compared to the JP Medical Equipment industry average (2x).


Next Steps

Future Growth

How is CYBERDYNE forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

62.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 7779 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.05%).

Earnings vs Market: 7779 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 7779's is expected to become profitable in the next 3 years.

Revenue vs Market: 7779's revenue (31.3% per year) is forecast to grow faster than the JP market (3.1% per year).

High Growth Revenue: 7779's revenue (31.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 7779's Return on Equity is forecast to be low in 3 years time (0.7%).


Next Steps

Past Performance

How has CYBERDYNE performed over the past 5 years?

19.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 7779 is currently unprofitable.

Growing Profit Margin: 7779 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 7779 is unprofitable, but has reduced losses over the past 5 years at a rate of 19.3% per year.

Accelerating Growth: Unable to compare 7779's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 7779 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-1.4%).


Return on Equity

High ROE: 7779 has a negative Return on Equity (-0.34%), as it is currently unprofitable.


Next Steps

Financial Health

How is CYBERDYNE's financial position?


Financial Position Analysis

Short Term Liabilities: 7779's short term assets (¥29.9B) exceed its short term liabilities (¥810.0M).

Long Term Liabilities: 7779's short term assets (¥29.9B) exceed its long term liabilities (¥2.7B).


Debt to Equity History and Analysis

Debt Level: 7779's debt to equity ratio (0.2%) is considered satisfactory.

Reducing Debt: 7779's debt to equity ratio has reduced from 71.6% to 0.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 7779 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 7779 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is CYBERDYNE's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 7779's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 7779's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 7779's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 7779's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 7779's dividend in 3 years as they are not forecast to pay a notable one for the JP market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

11.3yrs

Average board tenure


CEO

Yoshiyuki Sankai (61yo)

14.33yrs

Tenure

Mr. Yoshiyuki Sankai has been the President and Chief Executive Officer of CYBERDYNE Inc. since February 2006 and also serves as its Chairman. Mr. Sankai established CYBERDYNE, Inc. in June 2004. He has be ...


Board Members

NamePositionTenureCompensationOwnership
Yoshiyuki Sankai
Chairman14.33yrsno data37.53% ¥40.5b
Fumiyuki Ichihashi
Team Leader of Information Strategy Team & Director16yrsno datano data
Shinji Uga
Head of Corporate Unit & Director11.33yrsno data0.028% ¥30.1m
Cees Vellekoop
Outside Audit & Supervisory Board Member13yrsno datano data
Hikari Imai
Independent Outside Director5yrsno datano data
Kazumasa Yoshida
Independent Outside Director7yrsno data0.028% ¥30.1m
Kenichiro Okamura
Outside Audit & Supervisory Board Member9yrsno datano data
Hiroaki Kawamoto
Director16yrsno data0.0065% ¥7.0m
Kinichi Nakata
Independent Outside Director12yrsno datano data
Yutaka Fujitani
Outside Audit & Supervisory Board Member (Full-Time)9yrsno datano data

11.3yrs

Average Tenure

59yo

Average Age

Experienced Board: 7779's board of directors are seasoned and experienced ( 11.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

CYBERDYNE Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CYBERDYNE Inc.
  • Ticker: 7779
  • Exchange: TSE
  • Founded: 2004
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: JP¥108.001b
  • Shares outstanding: 215.14m
  • Website: https://www.cyberdyne.jp

Number of Employees


Location

  • CYBERDYNE Inc.
  • 2-2-1, Gakuen-Minami
  • Tsukuba
  • Ibaraki
  • 305-0818
  • Japan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
7779TSE (The Tokyo Stock Exchange)YesCommon SharesJPJPYMar 2014
8C4DB (Deutsche Boerse AG)YesCommon SharesDEEURMar 2014
CYBQ.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMar 2014
CYBQ.YOTCPK (Pink Sheets LLC)SPONSORED ADRUSUSDOct 2015

Biography

CYBERDYNE Inc. manufactures and sells medical devices in Japan. The company offers Hybrid Assistive Limb (HAL) for medical use for people who have disorders in the lower limb and leg weaknesses, as well as non-medical HAL; HAL peripherals; cleaning robots; transportation robots for various transportation tasks in factories, offices, and other indoor environments; and Acoustic X, a high speed light pulse LED array light source that enables real time photoacoustic imaging. It also provides HAL Therapy, a medical service to provide medical treatment for functional improvement of patients with cerebral, nervous, spinal cord injury, and cerebral embolism disorders; and non-medical services, such as HAL FIT and ROBO CARE training programs. The company was founded in 2004 and is headquartered in Tsukuba, Japan. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/06 17:43
End of Day Share Price2020/06/05 00:00
Earnings2020/03/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.